Company: IMRX
Filing Date: 2025-05-05
Form Type: 10-Q
Source: 0001790340-25-000061
Chunk: 353

Company: Immuneering Corp
Filing Date: 2025-05-05
Form: 10-Q
Item: Part I, Item 1
Chunk 353
---
 such time as we can generate revenue from product sales, if ever, we expect to finance our cash needs through a combination of equity offerings, debt financings, and potential collaborations, license and development agreements.

29

Cash Flows

The following table summarizes our sources and uses of cash for the periods indicated:

Three Months Ended March 31,20252024(in thousands)Net cash (used in) provided by:Operating activities$(14,081)$(15,491)Investing activities(9)21,393 Financing activities13,811 980 Net (decrease) increase in cash and cash equivalents$(279)$6,882 

Net Cash Used in Operating Activities

During the three months ended March 31, 2025, operating activities used approximately $14.1 million of cash, primarily resulting from our net loss of approximately $15.0 million and changes in assets and liabilities of $1.0 million, partially offset by stock-based compensation expense of approximately $1.7 million and the reduction in carrying amount of right-of-use assets of approximately $0.1 million.

During the three months ended March 31, 2024, operating activities used approximately $15.5 million of cash, primarily resulting from our net loss of approximately $14.3 million and changes in assets and liabilities of $2.7 million, partially offset by stock-based compensation expense of approximately $1.5 million and the reduction in carrying amount of right-of-use assets of approximately $0.1 million.

Net Cash (Used in) Provided by Investing Activities

During the three months ended March 31, 2025, investing activities used approximately $9 thousand of cash, primarily resulting from purchases of property and equipment of approximately $9 thousand. 

During the three months ended March 31, 2024, investing activities provided approximately $21.4 million, primarily resulting from the maturities of marketable securities of approximately $21.4 million, partially offset by purchases of property and equipment of approximately $37 thousand.

Net Cash Provided by Financing Activities

During the three months ended March 31, 2025, net cash provided by financing activities was approximately $13.8 million, primarily driven by proceeds of approximately $13.7 million from the issuance of common stock under the Company's ATM program, net of offering expenses, in addition to $0.1 million from the Company's employee stock purchase plan. 

During the three months ended March 31, 2024, net cash provided by